Your browser is no longer supported. Please, upgrade your browser.
Settings
CELG Celgene Corporation daily Stock Chart
CELG [NASD]
Celgene Corporation
IndexS&P 500 P/E18.16 EPS (ttm)5.25 Insider Own0.20% Shs Outstand759.12M Perf Week2.97%
Market Cap72.31B Forward P/E9.29 EPS next Y10.25 Insider Trans-1.87% Shs Float750.09M Perf Month-6.35%
Income4.21B PEG0.92 EPS next Q1.95 Inst Own81.10% Short Float1.92% Perf Quarter-5.06%
Sales13.00B P/S5.56 EPS this Y109.10% Inst Trans-5.81% Short Ratio2.04 Perf Half Y-25.33%
Book/sh8.95 P/B10.64 EPS next Y21.02% ROA9.70% Target Price124.23 Perf Year-19.72%
Cash/sh15.86 P/C6.01 EPS next 5Y19.70% ROE35.80% 52W Range88.32 - 147.17 Perf YTD-8.72%
Dividend- P/FCF14.56 EPS past 5Y25.80% ROI29.40% 52W High-35.68% Beta1.50
Dividend %- Quick Ratio4.80 Sales past 5Y18.70% Gross Margin96.50% 52W Low7.18% ATR2.83
Employees7467 Current Ratio5.00 Sales Q/Q16.90% Oper. Margin35.80% RSI (14)40.58 Volatility2.42% 3.08%
OptionableYes Debt/Eq1.24 EPS Q/Q187.30% Profit Margin22.60% Rel Volume0.74 Prev Close95.26
ShortableYes LT Debt/Eq1.24 EarningsJan 25 BMO Payout0.00% Avg Volume7.06M Price94.66
Recom2.20 SMA20-3.62% SMA50-7.92% SMA200-21.13% Volume723,356 Change-0.63%
Feb-13-18Upgrade Barclays Equal Weight → Overweight $105
Jan-26-18Reiterated SunTrust Buy $127 → $139
Jan-05-18Downgrade BofA/Merrill Buy → Neutral
Dec-27-17Downgrade Bernstein Outperform → Mkt Perform
Dec-22-17Reiterated Stifel Buy $149 → $130
Dec-08-17Upgrade Atlantic Equities Neutral → Overweight
Oct-27-17Upgrade Morgan Stanley Underweight → Equal-Weight
Oct-27-17Reiterated SunTrust Buy $156 → $127
Oct-27-17Reiterated Barclays Equal Weight $135 → $105
Oct-27-17Downgrade JMP Securities Mkt Outperform → Mkt Perform
Oct-26-17Downgrade Wells Fargo Outperform → Market Perform
Oct-24-17Initiated Guggenheim Buy $160
Oct-23-17Resumed Piper Jaffray Neutral $133
Oct-20-17Reiterated UBS Buy $153 → $146
Oct-20-17Downgrade Robert W. Baird Outperform → Neutral $162 → $136
Oct-20-17Downgrade Citigroup Buy → Neutral
Oct-17-17Initiated Bernstein Outperform
Oct-05-17Downgrade Morgan Stanley Equal-Weight → Underweight
Sep-15-17Reiterated Mizuho Buy $134 → $158
Sep-15-17Initiated RBC Capital Mkts Top Pick $176
Feb-20-18 07:00AM  Pharmaceutical Titans Senate Bid Will Test Voters Views on Drug Prices Bloomberg
Feb-19-18 08:43AM  Celgene Reports Positive Data on Dermatology Drug Otezla Zacks
07:32AM  Buy Biogen Stock on the Dip? Motley Fool
07:00AM  Is AbbVie or Gilead Sciences Stock a Better Buy? Motley Fool
Feb-17-18 04:00PM  OTEZLA® (Apremilast) Phase III Data Showed Significant Improvements in Patients with Active Behçets Disease with Oral Ulcers Business Wire
10:31AM  How Celgene Hopes to Cash In on CAR-T Motley Fool
Feb-16-18 01:28PM  What You Must Know About Celgene Corporations (NASDAQ:CELG) ROE Simply Wall St.
01:05PM  Why 2018 Could Be An Explosive Year For Biotech Mergers Investor's Business Daily
09:40AM  Billionaire Ray Dalio's Bridgewater Bets Big on ETFs: 13F Filing Investopedia
07:31AM  5 Things You Need to Know About Celgene's Future Motley Fool
Feb-15-18 02:32PM  [$$] Buying AMD, Intel, Union Pacific, Selling Wells Fargo Barrons.com
12:00PM  Celularity Announces $250M in Funding to Deliver Treatments for Cancer, Inflammatory and Degenerative Diseases, and Functional Regeneration PR Newswire
09:30AM  OTEZLA® (Apremilast) Phase II Data Showed Clinically Meaningful Improvements in Patients with Active Ulcerative Colitis Business Wire
09:00AM  Celgene Spinout Celularity Raises $250 Million To Develop Placental Cells To Attack Cancer Forbes
07:35AM  Celularity raises $250M to develop cell therapies: CEO CNBC Videos
07:30AM  [$$] Biotech Startup Celularity Launches With $250 Million The Wall Street Journal
07:30AM  Celgene Corporation Elects John Weiland to Its Board of Directors Business Wire
Feb-14-18 03:54PM  Tiger Management's Top 3 Sells Outweigh Top 3 Buys in 4th Quarter GuruFocus.com
08:33AM  Drugmaker CEO turned Senate hopeful: I met with Jamie Dimon on health care and like what he's doing CNBC
08:31AM  Celgene's Future Growth Could Depend on a Competitor's Trial This Quarter Motley Fool
07:37AM  Celgene announces additional $5 billion share buyback program MarketWatch
07:30AM  Celgene Announces Additional $5 Billion Share Repurchase Authorization Business Wire
06:39AM  Pharma industry is a competitive space, says former CEO CNBC Videos
06:00AM  How we can fix our broken health-care system: Former Celgene chief CNBC
Feb-12-18 12:40PM  Richard Pzena's Top 5 New Buys of the 4th Quarter GuruFocus.com
11:06AM  Former Celgene CEO Will Run for New Jersey Senate Seat Bloomberg
08:30AM  Todays Research Reports on Trending Tickers: Amgen and Celgene ACCESSWIRE
Feb-11-18 09:54AM  Stocks That Fell to 3-Year Lows in the Week of Feb. 9 GuruFocus.com
09:50AM  Weekly Top Insider Buys Highlight for the Week of Feb. 9 GuruFocus.com
09:37AM  Better Buy: Amgen Inc. vs. Celgene Motley Fool
Feb-09-18 07:30AM  Celgene Prices $4.5 Billion of Senior Unsecured Notes Business Wire
Feb-08-18 06:48PM  Stock Market Drop Not Seen Dampening Healthcare Deal Activity TheStreet.com
06:22PM  Top 3 Healthcare Stocks for 2018 Investopedia
12:19PM  Celgene Corporation -- Moody's rates Celgene's notes Baa2; stable outlook Moody's
08:55AM  Celgene Announces Offering of Senior Unsecured Notes Business Wire
Feb-07-18 12:57PM  Why Agios Pharmaceuticals Shares Jumped 37.8% in January Motley Fool
10:12AM  REGN vs. ALXN: Which Stock is Poised for Better Q4 Earnings? Zacks
06:48AM  Celgene Corp (CELG) Files 10-K for the Fiscal Year Ended on December 31, 2017 GuruFocus.com
Feb-06-18 05:45PM  These Biotechs Could Spring Back After Market Correction: Analyst Investor's Business Daily
05:10PM  Here's Why bluebird bio Soared 15% in January Motley Fool
07:30AM  Celgene Corporation Announces Positive Results from the Pivotal Phase III OPTIMISMM Study of POMALYST/IMNOVID® for the Treatment of Relapsed or Refractory Multiple Myeloma Business Wire
Feb-05-18 04:03PM  Here's Why BeiGene, Ltd. Jumped 38.9% in January Motley Fool -6.07%
09:46AM  The Zacks Analyst Blog Highlights: Sanofi, Seattle Genetics, AbbVie, Celgene and Vertex Zacks
08:49AM  Billionaire Fund Managers Are Bullish On These Biotech Stocks Insider Monkey
08:10AM  Why Juno Therapeutics Stock Screamed Higher in January Motley Fool
07:02AM  5 Top Stocks to Buy in February Motley Fool
Feb-03-18 10:47AM  3 Top Orphan-Drug Stocks to Buy Now Motley Fool
09:20AM  Top 5 Biotech Stocks for 2018 Investopedia
Feb-02-18 05:27PM  ACT NOW: Monteverde & Associates PC Investigates the Tender Offer of Juno Therapeutics, Inc. JUNO ACCESSWIRE
04:30PM  Biotech stocks hold up amid market sell-off CNBC Videos
08:00AM  Investor Expectations to Drive Momentum within Connecticut Water Service, Datawatch, Cadiz, Celgene, Texas Instruments, and Newfield Exploration Discovering Underlying Factors of Influence GlobeNewswire
07:30AM  Celgene Corporation Commences Tender Offer for Juno Therapeutics, Inc. Business Wire
06:33AM  3 Top Biotherapeutics Stocks to Buy Now Motley Fool
12:38AM  Behind the "games" drug companies play to stifle generic medicine CBS MoneyWatch
Feb-01-18 03:31PM  Is Celgene's Big Bet on CAR-T Smart? Motley Fool
07:30AM  Celgene Corporation to Webcast at Upcoming Investor Conferences Business Wire
07:18AM  Celgene Corporation (CELG): Heres What Polen Capital Thinks About It Insider Monkey
Jan-31-18 01:29PM  [$$] Bayer Buys More Crispr Stock After Celgene Sells Barrons.com
10:07AM  GRAPHIC-Biotech M&A explodes with $27.5 bln of January deals Reuters
07:33AM  The Best Arthritis Drug/Treatment Stocks on the Market Right Now Motley Fool
Jan-30-18 07:32PM  Alexandria Real Estate Equities Inc. (ARE) Q4 2017 Earnings Conference Call Transcript Motley Fool
02:35PM  Celgene Looking Good With Plans for More Growth Motley Fool
08:04AM  3 Big Biotech Stocks With Major Catalysts on the Way Motley Fool
07:16AM  3 Top Stocks Wall Street Is Overlooking Motley Fool
Jan-29-18 02:13PM  Dow Drops 70 Points Because Markets Don't Rise Forever Barrons.com
11:05AM  Celgene chairman to retire after 2 years in the role MarketWatch
10:54AM  Celgene Announces Retirement of Executive Chairman Bob Hugin and Appointment of CEO Mark Alles as Chairman of the Board of Directors Business Wire
09:35AM  Celgene Stock May Reward Bottom Fishers Investopedia
07:02AM  3 Biotech Stocks to Buy for 2018 Motley Fool
Jan-28-18 03:18PM  Better Buy: Intrexon Corporation vs. Celgene Motley Fool
01:10PM  5 biotech buyout candidates you should look at right now MarketWatch
11:34AM  3 Small Biotechs That Big Drugmakers Are Probably Drooling Over Motley Fool
Jan-27-18 03:17PM  3 Reasons Celgene's Investors Should Applaud the Juno Therapeutics Buyout Motley Fool
02:20PM  Big Biotech Is Bustling With Buyouts Motley Fool
02:00PM  2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs TheStreet.com
07:32AM  5 Things Celgene's Management Just Said That You'll Want to Know Motley Fool
Jan-26-18 01:13PM  Nate Pile Sells Some Nvidia, Buys More MannKind, Apple, And Celgene Forbes
09:20AM  Company News For Jan 26, 2018 Zacks
Jan-25-18 08:41PM  Biogen, Celgene Jump on Earnings; Ford's Acquisitions Fail to Move Stock--ICYMI TheStreet.com
07:15PM  Why 2018 Will Be Better for Biotech Deals Than 2017 TheStreet.com
04:47PM  With drug company M&A running high, $119M Redwood City biotech IPO surges 69% American City Business Journals
03:22PM  Celgene Says Juno, Impact Deals Won't Be Its Last TheStreet.com
11:50AM  Bluebird CAR-T still top Celgene priority after Juno deal Reuters
11:48AM  Celgene (CELG) Q4 Earnings & Sales Beat on Solid Revlimid Zacks
10:44AM  Biotech Earnings: Celgene Slides, Biogen Gains in Sector Stalemate Barrons.com
09:20AM  Celgene's profit, sales beat on continued Revlimid strength Reuters
09:16AM  Biotech Deals Are Costly. So Are In-House Clinical Failures Bloomberg
08:52AM  Celgene (CELG) Beats on Q4 Earnings Zacks
08:24AM  Stocks making the biggest moves premarket: CAT, MMM, CELG, LUV, NOC, F & more CNBC
08:16AM  Celgene reports 4Q loss Associated Press
07:53AM  Celgene's stock gains after profit beats expectations MarketWatch
07:41AM  Celgene posts quarterly loss vs. year-ago profit Reuters
07:33AM  Celgene on the Street: Analysts Recommendations in January Market Realist
07:30AM  Celgene Reports Fourth Quarter and Full-Year 2017 Operating and Financial Results Business Wire
06:43AM  Play Biotech Buyout Frenzy With These 2 Solid Funds Zacks
Jan-24-18 02:35PM  Behind Celgenes Strategy in the Juno Therapeutics Acquisition Market Realist
01:26PM  Why Investors Should Stay Long Eli Lilly and Co Stock InvestorPlace
01:05PM  How Juno Therapeutics Cellular Immunotherapy Portfolio Could Help Celgene Market Realist
12:40PM  WeissLaw LLP Investigates Juno Therapeutics Inc. Acquisition PR Newswire
11:32AM  Celgene to Acquire Juno Therapeutics Market Realist
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA, a small molecule inhibitor of the isocitrate dehydrogenase 2 to treat acute myeloid leukemia (AML); VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; and THALOMID to treat patients with MM and erythema nodosum leprosum. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for the treatment of patients with beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; CC-92480 to treat multiple myeloma; and durvalumab, an anti-PD-L1 antibody for multiple hematological cancers. The company has a strategic collaboration with BeiGene, Ltd. to advance a PD-1 Inhibitor program for solid tumor cancers. It also has collaborative agreements with Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; and Jounce Therapeutics, Inc. The company was founded in 1980 and is headquartered in Summit, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Alles Mark JSee RemarksFeb 08Buy91.903,260299,594178,904Feb 08 04:47 PM
VESSEY RUPERTSee remarksFeb 02Option Exercise0.005,62305,623Feb 05 04:39 PM
Smith Scott AndrewSee RemarksDec 19Option Exercise0.003,410046,233Dec 20 04:05 PM
KELLOGG PETER NSee RemarksDec 19Option Exercise0.003,410044,145Dec 20 04:04 PM
Curran TerrieSee remarksDec 19Option Exercise0.001,76505,690Dec 20 04:03 PM
Alles Mark JSee RemarksDec 19Option Exercise0.004,5500177,738Dec 20 04:02 PM
KAPLAN GILLADirectorDec 05Option Exercise24.979,250230,92685,551Dec 06 04:45 PM
MARIO ERNESTDirectorOct 30Option Exercise31.8013,600432,41271,024Nov 01 04:11 PM
KELLOGG PETER NSee RemarksOct 27Option Exercise0.002,100041,823Oct 31 04:10 PM
HUGIN ROBERT Jsee remarksOct 26Option Exercise31.8162,0201,972,5501,060,106Oct 26 04:44 PM
Curran TerrieSee remarksSep 25Sale143.891,727248,4983,925Sep 26 04:29 PM
KAPLAN GILLADirectorSep 12Option Exercise33.889,250313,39085,551Sep 14 04:35 PM
KAPLAN GILLADirectorSep 12Sale141.569,2501,309,43076,301Sep 14 04:35 PM
CASEY MICHAEL DDirectorSep 05Sale139.039,2501,286,0280Sep 06 06:53 PM
MARIO ERNESTDirectorAug 10Sale130.5218,5062,415,40369,424Aug 14 04:53 PM
KAPLAN GILLADirectorAug 02Sale134.527,5001,008,90076,301Aug 03 04:45 PM
Curran TerrieSee remarksAug 01Option Exercise0.001,50006,210Aug 02 04:38 PM
KELLOGG PETER NSee RemarksAug 01Option Exercise0.0060,000070,833Aug 02 04:37 PM
Smith Scott AndrewSee RemarksJul 28Option Exercise0.005,000045,415Aug 01 05:34 PM
PEHL MICHAEL F.See remarksJul 28Option Exercise0.002,50003,488Aug 01 04:56 PM
HUGIN ROBERT Jsee remarksJul 28Option Exercise0.0044,50001,021,159Aug 01 04:52 PM
Alles Mark JSee RemarksJul 28Option Exercise0.004,2000175,120Aug 01 04:48 PM
MARIO ERNESTDirectorJul 01Option Exercise0.00734087,930Jul 05 07:33 PM
LOUGHLIN JAMES JDirectorJul 01Option Exercise0.00734024,361Jul 05 07:33 PM
Friedman Michael ADirectorJul 01Option Exercise0.0073400Jul 05 07:31 PM
KAPLAN GILLADirectorJul 01Option Exercise0.00734083,801Jul 05 07:32 PM
CASEY MICHAEL DDirectorJul 01Option Exercise0.0073400Jul 05 07:30 PM
COX CARRIE SMITHDirectorJul 01Option Exercise0.00734023,880Jul 05 07:31 PM
BARKER RICHARD WDirectorJul 01Option Exercise0.00734012,066Jul 05 07:29 PM
LOUGHLIN JAMES JDirectorJun 26Option Exercise29.4318,500544,36332,877Jun 27 04:39 PM
LOUGHLIN JAMES JDirectorJun 26Sale133.5718,5002,471,04523,627Jun 27 04:39 PM
Friedman Michael ADirectorJun 22Option Exercise59.065,000295,3005,000Jun 23 04:04 PM
HUGIN ROBERT Jsee remarksJun 22Option Exercise29.49178,7205,271,0061,033,909Jun 23 04:02 PM
Friedman Michael ADirectorJun 22Sale135.005,000675,0000Jun 23 04:04 PM
HUGIN ROBERT Jsee remarksJun 22Sale134.14175,97023,604,616973,909Jun 23 04:02 PM
CASEY MICHAEL DDirectorJun 21Option Exercise33.889,250313,3909,250Jun 23 04:05 PM
Friedman Michael ADirectorJun 21Option Exercise59.065,000295,3005,000Jun 23 04:04 PM
Friedman Michael ADirectorJun 21Sale130.005,000650,0000Jun 23 04:04 PM
CASEY MICHAEL DDirectorJun 21Sale133.059,2501,230,7130Jun 23 04:05 PM
Friedman Michael ADirectorJun 19Option Exercise59.065,000295,3000Jun 20 04:07 PM
MARIO ERNESTDirectorJun 17Option Exercise0.00333087,196Jun 20 04:09 PM
LOUGHLIN JAMES JDirectorJun 17Option Exercise0.00333023,627Jun 20 04:08 PM
Friedman Michael ADirectorJun 17Option Exercise0.0033300Jun 20 04:07 PM
KAPLAN GILLADirectorJun 17Option Exercise0.00333083,067Jun 20 04:08 PM
CASEY MICHAEL DDirectorJun 17Option Exercise0.0033300Jun 20 04:07 PM
VESSEY RUPERTSee remarksJun 15Option Exercise104.164,007417,3584,785Jun 16 04:11 PM
MARIO ERNESTDirectorJun 15Option Exercise0.00375086,863Jun 16 04:11 PM
KAPLAN GILLADirectorJun 15Option Exercise0.00375082,734Jun 16 04:09 PM
LOUGHLIN JAMES JDirectorJun 15Option Exercise0.00375023,294Jun 16 04:10 PM
Haller Julia ADirectorJun 15Option Exercise0.003750575Jun 16 04:09 PM
Friedman Michael ADirectorJun 15Option Exercise0.0037500Jun 16 04:08 PM
BONNEY MICHAEL WDirectorJun 15Option Exercise0.003750375Jun 16 04:06 PM
CASEY MICHAEL DDirectorJun 15Option Exercise0.0037500Jun 16 04:06 PM
VESSEY RUPERTSee remarksJun 15Sale120.184,785575,0380Jun 16 04:11 PM
KAPLAN GILLADirectorJun 01Option Exercise28.979,250267,92682,359Jun 02 04:11 PM
CASEY MICHAEL DDirectorMay 30Option Exercise28.979,250267,926100,612May 31 04:10 PM
LOUGHLIN JAMES JDirectorMay 01Option Exercise28.969,250267,88032,169May 02 04:20 PM
LOUGHLIN JAMES JDirectorMay 01Sale124.009,2501,147,00022,919May 02 04:20 PM
HUGIN ROBERT Jsee remarksApr 10Option Exercise29.0260,0001,741,200973,909Apr 12 04:24 PM
KAPLAN GILLADirectorMar 30Sale123.8314,0331,737,70673,109Mar 31 05:31 PM
KAPLAN GILLADirectorMar 03Option Exercise25.587,500191,81387,142Mar 07 04:37 PM
VESSEY RUPERTSee remarksMar 01Sale124.424,000497,672778Mar 02 04:04 PM
CASEY MICHAEL DDirectorFeb 27Option Exercise25.587,500191,8507,500Mar 01 04:15 PM
CASEY MICHAEL DDirectorFeb 27Sale121.557,500911,6250Mar 01 04:15 PM
MARIO ERNESTDirectorFeb 27Sale121.2412,0001,454,88057,424Aug 31 04:03 PM